232 related articles for article (PubMed ID: 28977547)
21. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
22. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
McKeage K
Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
[TBL] [Abstract][Full Text] [Related]
23. DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS.
Vidrine DW; Berry JF; Garbuzov A; Falcon C; Tubbs RS; Bui CJ
Childs Nerv Syst; 2021 Jul; 37(7):2147-2151. PubMed ID: 34014367
[TBL] [Abstract][Full Text] [Related]
24. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
25. Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.
Ajimizu H; Kim YH; Mishima M
Med Oncol; 2015 Feb; 32(2):477. PubMed ID: 25556163
[TBL] [Abstract][Full Text] [Related]
26. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
Zhu V; Ou SH
Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
[TBL] [Abstract][Full Text] [Related]
27. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
Ou SH; Milliken JC; Azada MC; Miller VA; Ali SM; Klempner SJ
Lung Cancer; 2016 Jan; 91():70-2. PubMed ID: 26464158
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification.
Wang K; Guo R; Siegal GP; Wei S
Pathol Res Pract; 2019 Sep; 215(9):152535. PubMed ID: 31326196
[TBL] [Abstract][Full Text] [Related]
29. Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib.
Wong HH; Bentley H; Bulusu VR; Anyaegbu G; Watkins J; Horan G; Hatcher H
Anticancer Drugs; 2020 Nov; 31(10):1106-1110. PubMed ID: 32868646
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
Qiu X; Montgomery E; Sun B
Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
Takeuchi S; Murayama T; Yoshimura K; Kawakami T; Takahara S; Imai Y; Kuribayashi Y; Nagase K; Goto K; Nishio M; Hasegawa Y; Satouchi M; Kiura K; Seto T; Yano S
J Med Invest; 2017; 64(3.4):317-320. PubMed ID: 28955006
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory myofibroblastic tumors of the lung carrying a chimeric A2M-ALK gene: report of 2 infantile cases and review of the differential diagnosis of infantile pulmonary lesions.
Tanaka M; Kohashi K; Kushitani K; Yoshida M; Kurihara S; Kawashima M; Ueda Y; Souzaki R; Kinoshita Y; Oda Y; Takeshima Y; Hiyama E; Taguchi T; Tanaka Y
Hum Pathol; 2017 Aug; 66():177-182. PubMed ID: 28705706
[TBL] [Abstract][Full Text] [Related]
33. Inflammatory myofibroblastic tumor of the lung in children: anaplastic lymphoma kinase (ALK) expression and clinico-pathological correlation.
Siminovich M; Galluzzo L; López J; Lubieniecki F; de Dávila MT
Pediatr Dev Pathol; 2012; 15(3):179-86. PubMed ID: 22280150
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial.
Nagai H; Fukano R; Sekimizu M; Kada A; M Saito A; Asada R; Mori T
Nagoya J Med Sci; 2017 Aug; 79(3):407-413. PubMed ID: 28878445
[TBL] [Abstract][Full Text] [Related]
35. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
36. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary inflammatory myofibroblastic tumor harboring EML4-ALK fusion gene.
Sokai A; Enaka M; Sokai R; Mori S; Mori S; Gunji M; Fujino M; Ito M
Jpn J Clin Oncol; 2014 Jan; 44(1):93-6. PubMed ID: 24277751
[TBL] [Abstract][Full Text] [Related]
38. Vocal cord inflammatory myofibroblastic tumor with mucoid deposits harboring TIMP3-ALK fusion: A potential diagnostic pitfall.
Yorita K; Togashi Y; Nakagawa H; Miyazaki K; Sakata S; Baba S; Takeuchi K; Hayashi Y; Murakami I; Kuroda N; Oda Y; Kohashi K; Yamada Y; Kiyozawa D; Michal M; Michal M
Pathol Int; 2019 Jun; 69(6):366-371. PubMed ID: 31215130
[TBL] [Abstract][Full Text] [Related]
39. Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
Tamura T; Kiura K; Seto T; Nakagawa K; Maemondo M; Inoue A; Hida T; Yoshioka H; Harada M; Ohe Y; Nogami N; Murakami H; Kuriki H; Shimada T; Tanaka T; Takeuchi K; Nishio M
J Clin Oncol; 2017 May; 35(14):1515-1521. PubMed ID: 28296581
[TBL] [Abstract][Full Text] [Related]
40. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
Dong X; Fernandez-Salas E; Li E; Wang S
Neoplasia; 2016 Mar; 18(3):162-71. PubMed ID: 26992917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
